Min-Han Tan: LIQUIK is the world’s first prospective multi-center head-to-head liquid biopsy study

Quoting Min-Han Tan, CEO and Medical Director at Lucence Health, on LinkedIn:

”LIQUIK is the world’s first prospective multi-center head-to-head liquid biopsy study (NCT04703153).

A 3-way comparison was conducted between tissue sequencing, an FDA-approved ctDNA liquid biopsy test and Liquid Hallmark, an amplicon-based test, for the detection of 9 guideline-recommended biomarkers in lung cancer.

Interim results for the first 120 patients were reported at the IASLC World Conference on Lung Cancer (WCLC) (poster attached here).

So much appreciation to Richa Dawar from University of Miami who presented this work, and the study authors for the efforts!”

Source: Min-Han Tan/LinkedIn